Evidence map›Paper›PMID 39309809›Full record

ArticleHeliyon2024

Deciphering the multidimensional impact of

Zengwu Yao, Junping Han, Jinhui Wu, Miaomiao Li, Ruyue Chen, Mi Jian, Zhensong Yang, Xixun Wang, Yifei Zhang, Jinchen Hu and 1 more

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zengwu YaoYantai Yuhuangding Hospital, Shandong University, Shandong, China.
Junping HanYantai Yuhuangding Hospital, Shandong, China.
Jinhui WuYantai Yuhuangding Hospital, Shandong, China.
Miaomiao LiYantai Yuhuangding Hospital, Shandong, China.
Ruyue ChenYantai Yuhuangding Hospital, Shandong, China.
Mi JianYantai Yuhuangding Hospital, Shandong, China.
Zhensong YangYantai Yuhuangding Hospital, Shandong, China.
Xixun WangYantai Yuhuangding Hospital, Shandong, China.
Yifei ZhangYantai Yuhuangding Hospital, Shandong, China.
Jinchen HuYantai Yuhuangding Hospital, Shandong, China.
Lixin JiangYantai Yuhuangding Hospital, Shandong University, Shandong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: IGF-binding protein 1 ( Materials and methods: This study investigates genetic alterations affecting IGFBP1 expression in tumors using data from The Cancer Genome Atlas (TCGA) PanCancer Atlas via cBioPortal. We analyzed samples from 32 cancer types for mutation sites, including deep deletions, amplifications, and mutations. RNA-seq data were normalized using log2(value + 1). Statistical analyses, including survival outcomes, were conducted using R packages like ggplot2, stats, and car. Kaplan-Meier survival curves and log-rank tests assessed overall survival (OS) and progression-free survival (PFS). Univariate Cox regression was used to develop nomogram models for OS. Functional consequences of IGFBP1 mutations were explored through protein structure, stability, and IGF interaction analyses. Protein-protein interaction networks and functional enrichment were analyzed using GEPIA2, STRING, and Cytoscape. Gene Ontology (GO), KEGG, and Gene Set Enrichment Analysis (GSEA) provided insights into affected biological pathways. Results: Pan-cancer analysis revealed diverse expression patterns, including significant upregulation in cutaneous melanoma (SKCM) and downregulation in lung adenocarcinoma (LUAD) and stomach adenocarcinoma (STAD). Specifically, elevated IGFBP1 expression in SKCM patients led to a 25 % improvement in 5-year survival. In contrast, higher Conclusions: These findings highlight IGFBP1's potential as a biomarker and therapeutic target, particularly for immunoregulation and cancer subtype stratification.

Indexed as

Genetic alterationsIGFBP1Immune infiltrationPan-cancer analysisPrognosisTumor microenvironment

Identifiers

PMID39309809
PMCPMC11416238

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.